Results 191 to 200 of about 32,475 (204)
Some of the next articles are maybe not open access.
Immunity to chronic myelogenous leukemia
Hematology/Oncology Clinics of North America, 2004Given the high rate of cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia (CML), logical future treatment strategies will include combinations of tyrosine kinase inhibitors and immunotherapies such as vaccines. Increased understanding of highly specific immune responses will lead to novel and improved immunotherapy strategies ...
Dax Kurbegov, Jeffrey J. Molldrem
openaire +3 more sources
Juvenile Chronic Myelogenous Leukemia
Journal of Pediatric Hematology/Oncology, 1988Juvenile chronic myelogenous leukemia (JCML) is a malignant hematopoietic disorder of monocyte-histiocyte lineage that affects children less than 4 years of age. Since the disease represents only 2% of all childhood leukemias, experience with it has been limited even in large centers.
Zeev Estrov +2 more
openaire +2 more sources
Treatment of chronic myelogenous leukemia
American Journal of Health-System Pharmacy, 2016Treatment options for chronic-phase chronic myelogenous leukemia (CML) based on medication-resistant mutations in BCR-ABL are reviewed.Imatinib, nilotinib, and dasatinib are first-line therapies for chronic-phase CML. Nilotinib or dasatinib can be used as first- or second-line treatment, with nilotinib preferred in patients with BCR-ABL F317 and V229 ...
Christine Kujak, Jill M. Kolesar
openaire +2 more sources
Therapy of chronic myelogenous leukemia
Cancer, 1987While the demonstrated antiviral, antiproliferative, and immunomodulatory properties of interferons have led to a number of theories regarding their potential use in treating individuals with chronic myelogenous leukemia (CML), their limited availability has prevented thorough clinical investigation.
Michael J. Keating +5 more
openaire +3 more sources
Chronic myelogenous leukemia in chronic phase
Current Treatment Options in Oncology, 2001Chronic myelogenous leukemia (CML) is a clonal myeloproliferative disorder characterized by genomic instability leading to its inevitable clinical evolution from an easily controlled chronic phase to a terminal blastic phase. The molecular abnormality responsible for this disease--BCR-ABL--and the critical biochemical aberrations resulting from it have
Moshe Talpaz +2 more
openaire +3 more sources
Chronic myelogenous leukemia in the dog
Journal of the American Veterinary Medical Association, 1983SUMMARY Chronic myelogenous leukemia was diagnosed in 7 dogs. In each case, marked neutrophilia in the absence of infection was observed in association with nonspecific illness. Diagnosis was based on morphologic cytology of blood smears, bone marrow aspirates, and in 1 case, a lymph node biopsy specimen.
C E, Leifer +3 more
openaire +2 more sources
Chronic myelogenous leukemia of childhood
The Indian Journal of Pediatrics, 1987Chronic myelogenous leukemia is relatively uncommon in childhood, occurring as both an “adult” and “juvenile” form. The clinical presentation and course are fairly well defined, especially for the adult type. Though extensive advances in understanding the pathogenesis and cytogenetics of the adult form have been made in the last 25 years, treatment is ...
openaire +3 more sources
Coexistence of chronic myelogenous leukemia and chronic lymphocytic leukemia
Cancer, 1984A 55-year-old man is reported who initially developed chronic lymphocytic leukemia. Seven years later, after chemotherapy with chlorambucil, chronic myelogenous leukemia was diagnosed in addition to the chronic lymphocytic leukemia. Four previously reported cases with the same sequence of events are reviewed as well as cases of chronic myelogenous ...
Morton R. Axelrod +2 more
openaire +3 more sources
Hypofibrinogenemia in Chronic Myelogenous Leukemia
JAMA: The Journal of the American Medical Association, 1979To the Editor.— Favis and his colleagues (240:1953, 1978) state that as a complication of chronic myelogenous leukemia hypofibrinogenemic bleeding "has been reported only once previously." They overlooked three other case reports.1-3One1of these three patients also had chloromas containing sea-blue histiocytes, and in the other two patients,2,3blastic
openaire +3 more sources